Skip to content
Datasets/FM-AD

Foundation Medicine Adult Cancer Clinical Dataset (FM-AD)

Underused opportunityMixedProject-curated
FMAvailable from GDC

18,004 patients profiled with a targeted clinical panel - the largest cohort in the Genomic Data Commons, with no informative vital status, no race data, and no treatment records.

Can it answer your research question?

0 of 6 supported
  • Overall survival

    Not supported

    Vital status is recorded for every case and informative for none.API

  • Progression or recurrence

    Not supported

    progression_or_recurrence is informative for no case in the harmonized records.API

  • Treatment response

    Not supported

    treatment_outcome is populated for no case in the harmonized records.API

  • Which drug was given

    Not supported

    therapeutic_agents is recorded for no case in the harmonized records.API

  • Stage-adjusted modelling

    Not supported

    ajcc_pathologic_stage is informative for no case in the harmonized records.API

  • Analysis by race or ethnicity

    Not supported

    Race is informative for no case in the harmonized records.API

Judged from the repository’s own field completeness (thresholds). “Not measured” means we have not probed that field for this record, not that the data lack it.

At a glance

Every percentage is the repository’s own record of what is filled in
CasesAPI
18,004
Measurement types
2
54,096 files, 288 MB
Follow-upAPI
None recorded
no survival endpoint
Treatment responseAPI
Not recorded

SubjectCALC

Pan-cancer

As filed by the repository

Not ReportedCystic, Mucinous and Serous NeoplasmsMiscellaneous TumorsGerm Cell NeoplasmsComplex Mixed and Stromal NeoplasmsThymic Epithelial NeoplasmsDuctal and Lobular NeoplasmsAdnexal and Skin Appendage NeoplasmsTransitional Cell Papillomas and CarcinomasMeningiomasMesothelial NeoplasmsMucoepidermoid Neoplasms

Who is in the cohortAPI

A usable value“Not reported” or “unknown”No value recorded
  • Sex10,197 female · 7,798 male · 9 unknown
  • Race18,004 not reported
  • Ethnicity18,004 not reported
  • Vital status18,004 not reported

Age at diagnosis

Median 59, middle half 50–67, range 19–89 years across 12,000 cases.

What was measured, and on how many

2 measurement types, 2 covering the whole cohort.

  • Targeted DNA panel sequencing18,004 of 18,004 · 100%
  • Clinical18,004 of 18,004 · 100%
Platform, files and data levels
AssayPlatformFilesLevels
Targeted DNA panel sequencingAPIillumina54,012-
ClinicalAPI-42-
How complete all 29 clinical fields are - 5 informative for at least 80% of cases

A field counts as informative only when it holds a real value. “Not reported” blocks an analysis just as a missing field does. Fields marked 1:n can hold several records per case, so they show the share of cases with any record.

Informative - a usable valuePresent but uninformative - “not reported” or “unknown”Absent - no value recorded

Outcome

  • Vital statusAPI0%
  • Cause of deathAPI0%
  • Progression or recurrenceAPI0%
  • Last known disease statusAPI0%

Follow-up

  • Disease response at follow-upAPI0%
  • Progression at follow-upAPI0%
  • ECOG performance statusAPI0%

Treatment

  • Prior treatmentAPI0%
  • Treatment typeAPI0%
  • Treatment givenAPI0%
  • Therapeutic agentsAPI0%
  • Treatment outcomeAPI0%
  • Regimen or line of therapyAPI0%

Staging

  • AJCC pathologic stageAPI0%
  • AJCC clinical stageAPI0%

Diagnosis

  • Primary diagnosisAPI99%
  • Tissue or organ of originAPI90%
  • Prior malignancyAPI0%
  • Synchronous malignancyAPI0%

Pathology

  • Morphology (ICD-O)API99%
  • Classification of tumorAPI86%
  • Tumor gradeAPI0%

Demographics

  • Sex at birthAPI100%
  • RaceAPI0%
  • EthnicityAPI0%
  • Population groupAPI0%
  • Country of residenceAPI0%

Exposure

  • Tobacco smoking statusAPI0%
  • Alcohol historyAPI0%

Access

MixedSome components are open; others need approval.

Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required

Open components
84 open-access files
Controlled components
54,012 controlled-access files
Typical turnaround
days to a few weeks after signing official approval
License
NIH Genomic Data Sharing Policy terms
Citation requirement
Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.

What it is good for

Written and checked by a reviewer, not generated from metadata.

  1. 1. What are the mutation frequencies and co-occurrence patterns of clinically targeted genes in a large real-world oncology population?

    Needs approved accessn ≈ 18,004HUMAN

    18,004 patients profiled on a clinical panel give tight confidence intervals on alteration frequencies, including for alterations too rare to study in a thousand-patient research cohort. Frequency and co-occurrence need only the variant calls and the tumor type, both of which are present.

    Statistical note: Panel composition bounds what can be counted: absence of a gene from the panel is not absence of alteration. Report frequencies only for genes on the panel and state the panel version.

    NeedsTargeted DNA paneldiagnoses.primary_diagnosis
  2. 2. How does the mutational landscape of clinically sequenced patients differ from that of research cohorts such as TCGA?

    Needs another datasetn ≈ 18,004HUMAN

    Clinical sequencing populations are enriched for advanced and pretreated disease relative to the largely treatment-naive primary tumors in research cohorts. With 18,004 cases the comparison is well powered, and the discrepancy is itself a caution about generalising research-cohort findings to clinical practice.

    Statistical note: Restrict the comparison to genes present on both assays and to matched tumor types; differences in assay sensitivity and tumor purity confound naive comparisons.

    NeedsTargeted DNA panel
  3. 3. How common are actionable alterations across tumor types in routine practice?

    Needs approved accessn ≈ 18,004HUMAN

    Scale plus a clinically-deployed panel makes this the right cohort for estimating what fraction of patients would be eligible for a given targeted therapy, a question that research cohorts systematically answer wrong.

    Statistical note: Eligibility estimates apply to the population that received clinical sequencing, which is not the whole cancer population.

    NeedsTargeted DNA panel

What it cannot tell you

3 blocking

Written by a reviewer against the source, not inferred from what is missing.

BlockingMissing dataHUMAN

Vital status is populated for 100% of the 18,004 cases and informative for 0%: every value is "not reported". Progression or recurrence and last known disease status show the same pattern - fully populated, entirely uninformative. No outcome endpoint of any kind can be derived.

Affects: Survival analysis; Prognostic modeling; Any outcome-anchored question

Mitigation: None. Choose a different cohort for any outcome question.

BlockingTreatment contextHUMAN

Every treatment field is empty for every case: prior treatment, treatment type, therapeutic agents, treatment outcome and line of therapy are all at 0% coverage.

Affects: Treatment-response analysis; Resistance mechanisms; Line-of-therapy questions

Mitigation: None. Note that this is a clinically sequenced and therefore largely pretreated population, so alteration frequencies reflect an unrecorded treatment history.

BlockingPopulation coverageHUMAN

Race is recorded as "not reported" for all 18,004 patients. The largest cohort the Genomic Data Commons holds contributes nothing to any question about how cancer genomics differs across populations.

Affects: Disparities research; Ancestry-stratified analysis

Mitigation: Germline-based ancestry inference is not appropriate here; the assay is a tumor-only targeted panel and the consent scope does not contemplate it.

MajorAscertainment biasHUMAN

Patients enter this cohort by being referred for clinical tumor sequencing, which selects for advanced disease, access to specialist care and insurance coverage.

Affects: Population frequency estimates; Generalization to all patients

Mitigation: Describe results as applying to clinically sequenced patients, not to all patients.

MajorAccess constraintHUMAN

54,012 of 54,096 files are controlled access; only 84 files are open.

Affects: Everything except catalog browsing

Mitigation: Confirm from this page that your question survives the annotation gaps before starting an access request, because scoping with open files is not possible at this ratio.

Not appropriate for

  • Any survival, prognostic or outcome analysis. - Vital status is uninformative for all 18,004 cases.HUMAN
  • Any treatment or resistance analysis. - All treatment fields are empty.HUMAN
  • Any analysis of racial or ethnic differences. - Race is "not reported" for every patient in the cohort.HUMAN
  • Estimating population-level mutation prevalence. - The cohort is ascertained by clinical referral for sequencing and carries no sampling frame or denominator.HUMAN

Who has used it

Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.

Analyzed the dataCALC2
6
accession in the methods section
Declared using it
6
named in a data availability statement
Cited the paper
-
attention to the publication, not reuse of the data
Against expectation
Well below
about 45 articles expected; index -2.71

What articles did with it

Only the last row counts as reuse. Where the accession appears in an article tells us what the authors did with the data.

  • Mentioned the dataset0
  • Accession found in text6
  • Declared using it6
  • Analyzed the data6

Against comparable datasets

6 articles analyzed these data. About 45 would be expected. The expectation comes from a model of size, age, breadth and access tier.

  • Analyzed it6
  • Expected~45
More articles are listed below than the count
The headline count is deliberately narrow: one section of one accession (METHODS:"phs001179"), so every dataset in the corpus is counted the same way and the numbers can be compared. The 7 articles listed below were retrieved and graded one at a time, and an article counts as having analyzed the data wherever the accession sits in the analysis - methods, results, tables, figures or supplement - under any of this dataset’s accessions. Read the list as the evidence about these articles, and the count as the number that is comparable across datasets.
Why this is an underused opportunity
  • 6 article(s) reference this dataset's accession in a methods section, against 44.8 predicted for datasets of comparable size, age, modality breadth and access tier (reuse gap index -2.71 on a log2 scale, 3rd percentile of the assessed corpus).

Compared against 132 datasets in this corpus with a citable accession and sufficient metadata. See Methods for the model.

Possible original publication, unverified

No repository or reviewer names this dataset’s marker paper, so this is the pipeline’s own guess: the earliest heavily cited article that analysed the accession and names it in full text. Nothing is counted from it - not the citation figure above, not the funding attribution - and it is queued for review rather than presented as fact.

Articles that analyzed the data

Examples, not the full list. 10 articles matching this dataset's accession search were retrieved and graded individually; these are the strongest of those.

Deep-review sample: author overlap and funding were checked only for the 9 articles listed here, not for every article examined. Of the 7 that analyzed the data, author overlap with the generating team could not be checked for any of them, and 2 of the 7 we could check were themselves NCI-funded. These are sample counts, not population estimates.

2 articles with weaker evidence

These name the dataset, but we could not confirm the data were analyzed. Shown for completeness and not counted as reuse.

Community examples

Share your example

Analyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.

beginner

Which classes of analysis do this cohort's clinical records actually support, and which are ruled out before I request access?

Audit whether this dataset can answer your question

CD2S workbooks · ran 21 Sept 2026
pythonabout a minuteexecuted
Required inputs
  • A GDC project identifier
  • Network access to api.gdc.cancer.gov
Expected outputs
  • Per-field coverage table separating populated from informative values
  • Assay coverage as a percentage of the cohort
  • A yes/no verdict for six common analysis classes
  • A chart contrasting populated with informative coverage, field by field
Steps
  1. Fetch project summary and per-assay case counts
  2. Request facet counts for the clinical fields that gate common analyses
  3. Separate absent fields from fields populated with non-answers
  4. Flag one-to-many fields where per-case percentages cannot be inferred
  5. Retrieve case-level fields and test whether a survival endpoint is derivable
  6. Print a verdict for each analysis class

Start here

Starter code generated from this record’s own identifiers, then the access steps.

Get the data in code

GDC: list open files and download thempython

Open-access files need no account. Controlled files need an approved dbGaP request and a token passed to gdc-client.

import json, requests

PROJECT = "FM-AD"
filters = {"op": "and", "content": [
    {"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
    {"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
          "fields": "file_id,file_name,data_category,data_type,file_size",
          "size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")

# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
    fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txt
GDC: clinical table for every casepython
import json, requests

filters = {"op": "in", "content": {"field": "project.project_id", "value": ["FM-AD"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
          "fields": ",".join([
              "submitter_id", "demographic.vital_status", "demographic.days_to_death",
              "diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
              "diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("FM-AD_clinical.tsv", "w").write(tsv)
This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-fm-ad.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
    print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'

Access steps

  1. 1
    Check your question against the annotation gaps aboveFor people15 minutes

    Almost all files are controlled, so scoping after approval is expensive. The three blocking limitations on this page rule out most reasons people arrive at a cohort of this size.

  2. 2
    Submit a dbGaP data access request if the question survivesFor peopledays to a few weeks

    Requires: eRA Commons account, institutional signing official approval

    https://gdc.cancer.gov/access-data/obtaining-access-controlled-data
  3. 3
    Query the project from code, with no credentialsFor agents

    The file index is public even where files are not, so an agent can size the cohort before anyone requests access.

    curl -s 'https://api.gdc.cancer.gov/files' --get \
      --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["FM-AD"]}}' \
      --data-urlencode 'fields=file_id,file_name,data_type' \
      --data-urlencode 'size=10000' --data-urlencode 'format=TSV'
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

  4. 4
    Pass the token when the agent needs controlled filesFor agents

    Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.

    Requires: GDC authentication token

    curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

Provenance

All of it, and more, is in this record’s JSON.

Identifiers

Versions and verification

Released
1 Jan 2017
Metadata retrieved
18 Sept 2026
Review status
Project-curatedCD2S project curation on 18 Sept 2026
Data generation funding
Funded data generation

Funding

Awards resolved through NIH RePORTER. Awards that paid to generate these data are listed apart from awards that paid to reuse them. Both are returns on NCI investment, but different ones.

Funded reuse of these data

  • T32CA009172Physician Scientist Training in Cancer ResearchJennifer R Brown, James A. DeCaprioFY1985-2026API
  • R01CA227388Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsEliezer M Van AllenFY2018-2022API
  • R01CA203636Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentMizuki NishinoFY2017-2021API
  • K08CA234458Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational OncologyDavid LiuFY2018-2022API
  • T32CA009666T32 Research Training in Academic Medical OncologyMichael Davies, Courtney DiNardoFY1994-2026API

Funded infrastructure or harmonization

  • U01CA209414The Boston Lung Cancer Survival CohortDavid C ChristianiFY2017-2026API
  • P30CA008748Antitumor AssessmentElisa de Stanchina, FRANCESCA M GANYFY1985-2026API
  • U01CA247760Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing DataKen ChenFY2020-2022API

For softwarerecord JSON